Bob assists venture-backed startups, mid-sized companies, basic research institutes, as well as large biopharmaceutical companies related to worldwide patent and trademark acquisition and strategic counseling in the biotechnology arts, including molecular biology, antibodies/peptibodies, protein therapeutics, cancer therapies, gene therapy, cellular immunotherapy, and nucleic acids; as well as next generation sequencing and modern genomics, including microfluidics, microarrays, bioinformatic and pharmacogenomic analysis for personalized medicine and companion diagnostics. Bob’s practice includes preparing and prosecuting U.S. and foreign patent applications, patent landscape analysis, opinion work, including patentability, non-infringement, invalidity and freedom-to-operate opinions. He also provides due diligence analysis in connection with venture capital, public and private financing, mergers & acquisitions; as well as litigation support, post-Grant Oppositions, and worldwide Trademark procurement and enforcement strategy.
Bob has extensive Biopharma industry experience where he participated in hundreds of detailed global patent strategy decisions for high value IP assets. As part of an extensive patent strategy, Bob co-managed the expedited generation of a lead recombinant protein and its accelerated pre-clinical development to acceptance for First-In-Human clinical trials. Bob practiced at Amgen for over 10 years, where he was the lead IP Attorney for 2 commercial and 2 Phase I biologics. Bob also managed the worldwide procurement and enforcement strategy for a trademark portfolio comprising hundreds of registered trademarks protecting numerous pharmaceutical products.